

RECEIVED

JUN 1 3 2002

SUBMISSION UNDER MPEP 609 D


Page 1 of 1

Application Number	10/017 180 E B 160	risann
Filing Date		hitaaa
First Named Inventor	Wiegand	
Group Art Unit		
Examiner Name		1
Attorney Docket Number	JBP-571	

		Tage TOLT			.1
		U.S. PAT	ENT DOCUMENTS		
		Name of Patentee or Applicant	U.S. Patent Document		Pages, Columns, Lines,
Examiner Initials	Cite No. ¹	of Cited Document	Number	Kind Code ² (if known)	where relevant passages or relevant figures appear
V.C		Johnson & Johnson Consumer Companies, Inc.	USSN 10/012,626		
KG		Companies, inc.	our docket JBP-575		
		Johnson & Johnson Consumer Companies, Inc.	USSN 10/012,627		
		Companies, inc.	our docket JBP-570		
		Johnson & Johnson Consumer Companies, Inc.	USSN 09/676,876		p.10 of JBP-575
		Companies, inc.	Our docket JBP-521		
		Johnson & Johnson Consumer	USSN 60/256,812		p.24 of JBP-571
KG		Companies, Inc.	Our docket JBP-531		,
<u> </u>					
					1

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, where relevant passages or relevant figures appear Foreign Patent Document Name of Patentee or Examiner Initials Cite Applicant of Cited Document Office³ Number⁴ KindCode⁵ OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T^2 Examiner Cite title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), No.1 volume-issue number(s), publisher, city and/or country where published Initials*

	<u> </u>			
Examiner	LataM-/	Date	6/18/03	



JUN 1 3 2002

O 1 P E 70002 U

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 4

TOTAL CHIE CONTROL HUMBON.
10/017,180
December 7, 2001
Wiegand
1614
JBP-571

		U.S. Patent Do	ocument			
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
a±						
 						

LLC DATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant T⁶ mm-dd-yyyy **Applicant of Cited Document** Initials figures appear Number⁴ KindCode⁵ Office³ No.1 K6 JP JP11 19076 Pola Chemical Industrial Co., Ltd. 01-26-1999 T Ŧ JP JP9227399 Pola Chemical Industrial Co., Ltd. 09-02-1997

Examiner	X-t-MC	Date	Clista	
Signature	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Considered	e li us	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



JUN 1 3 2002

PTO/SB/08A (08-00)

Approved for use through U.S. Patent and Trademark Office: U.S.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 4

a collection of information unless it displays a valid OMB control number.		
Application Number	10/017,180	
Filing Date	December 7, 2001	
First Named Inventor	Wiegand	
Group Art Unit	1614	
Examiner Name		
Attorney Docket Number	JBP-571	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
K6		WILLIAM J. CUNLIFFE, Acne, 1989, 1-11, Martin Dunitz Ltd., UK.	
		S. COHEN, T. KAMARCK, R. MERMELSTEIN, A Global Measure of Perceived Stress, Journal of Health and Social Behavior 1983, 385-396, Vol 24 (December).	
		P. BRANTLEY, C. WAGGONER, G. JONES, N. RAPPAPORT, A Daily Stress Inventory: Development, Reliability, and Validity, Journal of Behavioral Medicine,1987:61-75, Vol. 10, No.1.	
		T.R. COOPER, H.R. TRUNKFIELD, A.J. ZANELLA, W.D. BOOTH, An enzyme-linked Immunosorbent Assay for Cortisol in the Saliva of Man and Domestic Farm Animals, Journal of Endocrinology (1989) R13-R16.	
		A. BECK, G. BROWN, N. EPSTEIN, R. STEER, An Inventory for Measuring Clinical Anxiety: Psychometric Properties, Journal of Consulting and Clinical Psychology, 1988, 893-897, Vol. 56, No. 6.	
		A. BUSKE-KIRSCHBAUM, S. JOBST, A. WUSTMANS, C. KIRSCHBAUM, W. RAUH, D. HELLHAMMER, Attenuated Free Cortisol Response to Psychosocial Stress in Children with Atopic Dermatitis, Psychosomatic Medicine, 1997:419-426, Vol. 59.	
		A. SLOMINSKI, J. WORTSMAN, T. LUGER, R. PAUS, S. SOLOMON, Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress, Physiological Reviews, July 2000:979-1020.Vol. 80, No.3.	
		M. MOROHASHI, M. TOYADA, Y. LUO, S. HIGAKI, Cutaneous Neurologic Factors are Involved in the Pathogenesis of Acne, The Journal of Investigative Dermatology:820.,2000, Vol. 114 (Abstract)	
		E. AARDAL, A. CHARLOTTE HOLM, Cortisol in Saliva-Reference Ranges and Relation to Cortisol in Serum, European Journal Clin Chem, Clin Biochem 1995: 927-932, 33(No 12).	
		D. WATSON, L. CLARK, A. TELLEGEN, Development and Validation of Brief Measures of Positive and Negative Affect: The PANAS Scales, Journal of Personality and Social Psychology, 1988:1063-1070, Vol.54, No. 6.	
		O. WOLKOWITZ, V. REUS, A. KEEBLER, N. NELSON, M. FRIEDLAND, L. BRIZENDINE, E. ROBERTS, Double-Blind Treatment of Major Depression with Dehydroepiandrosterone, Am. J. Psychiatry, April 1999: 646-649, 156:4.	
		F. DHABHAR, B. MCEWEN, Enhancing versus suppressive effects of stress hormones on skin immune function, Proc. Natl. Acad. Sci. USA. 6(February 1999):1059-1064.,Vol. 96.	
		P. SCHULZ, W. SCHLOTZ, Trierer Inventar zur Erfassung von chronischem Streß (TICS), , Diagnostica 45, Heft 1, Hogrefe Veriag Gottingen 1999: 8-19	
		M. HOROWTIZ, N. WILNER, W. ALVAREZ, Impact of Event Scale: A Measure of Subjective Stress, , Psychosomatic Medicine, (May 1979):209-218, Vol 41, No. 3.	
KG		P. HUNT, E. GURNELL, F. HUPPERT, C. RICHARDS, A. PREVOST, J. WASS, J. HERBERT, V. CHATTERJEE, Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison's Disease in a Randomized, Double Blind Trial, The Journal of Clincial Endocrinology & Metabolism, 2000:4650-4656, Vol 85, No. 12.	

Examiner	V 1 10 C	Date
Signature	KusyN-6-	Considered 6.63-63

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

JUN 1 3 2002

Approved for

~U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 4

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

	Г	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
166		M. CHREN, R. LASEK, S. FLOCKE, S. ZYZANSKI, Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases, Arch Dermaology, Nov. 1997:1433-1440, Vol 133.	
		J. KABAT-ZINN, E. WHEELER, T. LIGHT, A. SKILLINGS, M. SCHARF, T. CROPLEY, D. HOSMER, J BERNHARD, Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients with Moderate to Severe Psoriasis Undergoing Phototherapy (UVB) and Photochemotherapy(PUVA), Psychosomatic Medicine (1998):625-632, Vol. 60.	
		J. KIECOLT-GLASER, R. GLASER, E. STRAIN, J. STOUT, K. TARR, J. HOLLIDAY, C. SPEICHER, Modulation of Cellular Immunity in Medical Students, Journal of Behavioral Medicine, (1986):5-21., Vol.9, No. 1.	
		N. BOLGER, E. SCHILLING, Personality and the Problems of Everyday Life: The Role of Neuroticism in Exposure and Reactivity to Daily Stressors, Journal of Personality, September 1991: 355-386, 59:3.	
		M. SULZBERGER, S. ZAIDENS, Psychogenic Factors in Dermatologic Disorders, 1948:669-685.	
		A. GARG, M. CHREN, L. SANDS, M. MATSUI, K. MARENUS, K. FEINGOLD, P. ELIAS, Psychological Stress Perturbs Epidermal Permeability Barrier Homeostasis, Implications for the Pathogenesis of Stress-Assoicated Skin Disorders, Arch Dermatol, (Jan 2001)53-59, Vol. 137.	
		E. PANCONSESI, G. HAUTMANN, Psychophysiology of Stress in Dermatology:The Psychobiologic Pattern of Psychosomatics, Dermatologic Clinics, (July 1996):399-421., Vol. 14, Number 3.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychobiological Research:An Overview, Neuropsychobiology 1989:150-169, Vol. 22.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychoneuroendocrine Research:Recent Developments and Applications, Psychoneuroendocrinology, 1994, 313-333, Vol 19, No. 4.	
		M. DENDA, T. TSUCHIYA, P. ELIAS, K. FEINGOLD, Stress alters cutaneous permeability barrier homeostatis, Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2000:R367-R372., Vo. 278.	
		R. A. DRESSENDORFER, C. KIRSCHBAUM, W. ROHDE, F. STAHL, C.J. STRASBURGER, Synthesis of a Cortisol-Biotin Conjugate and Evaluation as a Tracer in an Immunoassay for Salivary Cortisol Measurement, J. Steroid Biochem, Molec. Biol. 1992, 683-692, Vol 43, no. 7.	
16		A. DELONGIS, S. FOLKMAN, R. LAZARUS, The Impact of Daily Stress on Health and Mood:Psychological and Social Resources as Mediators, Journal of Personality and Social Psychology, 1988:486-495, Vol 54, No. 3.	

Examiner / 1 / 1	Date 6.19 B
Signature	Considered 6.19.13

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JUN 1 3 2002

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 4 of 4

a collection of information unless it displays a valid Olyb control flumber.				
Application Number	10/017,180			
Filing Date	December 7, 2001			
First Named Inventor	Wiegand			
Group Art Unit	1614			
Examiner Name				
Attorney Docket Number	JBP-571			

Examiner's Initials* Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published G. CHROUSOS, P. GOLD, The Concepts of Stress and Stress System Disorders: Overview Physical and Behavioral Homeostasis, Stress and Stress Disorders-Chrousos & Gold, JAN March 4, 1992:1244-1252.Vol. 267, No. 9. R. SAPOLSKY, Why Zebras Don't Get Ulcers, W. H. Freeman and Company, New Yor 1998:1-18. TAUSK ET AL., Stress and the Skin, Arch Dermatol. Jan 2001:78-82, Vol. 137. SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J. ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the simmune system, Experimental Dermatology, 1998:7:81-96, Denmark. Www.shiseido.co., publicly available prior to December 7, 2001.	
Physical and Behavioral Homeostasis, Stress and Stress Disorders-Chrousos & Gold, JAM March 4, 1992:1244-1252.Vol. 267, No. 9. R. SAPOLSKY, Why Zebras Don't Get Ulcers, W. H. Freeman and Company, New Young 1998:1-18. TAUSK ET AL., Stress and the Skin, Arch Dermatol. Jan 2001:78-82, Vol. 137. SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J. ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the simmune system, Experimental Dermatology, 1998:7:81-96, Denmark.	
1998:1-18. TAUSK ET AL., Stress and the Skin, Arch Dermatol. Jan 2001:78-82, Vol. 137. SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J. ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the simmune system, Experimental Dermatology, 1998:7:81-96, Denmark.	erview of I, JAMA,
SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the simmune system, Experimental Dermatology, 1998:7:81-96, Denmark.	w York,
SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the simmune system, Experimental Dermatology, 1998:7:81-96, Denmark.	
www.shiseido.co. , publicly available prior to December 7, 2001.	
	·

Examiner Signature Considered 6-19-63					
Signature Considered Considered	Exa	miner V	ha c	Date	1
	Sig	nature Last	71120-	Considered	6.1716

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.